Related Experiment Video
Updated: Mar 19, 2026
12:30
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
10.2K
Harnessing gene and drug delivery for vascularizing engineered tissue platforms
Gabrielle C Lam1, Michael V Sefton2
1Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Drug Discovery Today
|June 21, 2016
Summary
Enhancing tissue vascularization is key for treating ischemic diseases and regenerating tissues. New gene and drug delivery methods improve blood vessel growth in engineered tissues, aiding therapeutic cell engraftment.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Vascular Biology
Background:
- Tissue vascularization is critical for treating ischemic conditions and enabling tissue regeneration.
- Successful engraftment of therapeutic cells depends on adequate blood supply.
- Understanding angiogenic mechanisms is essential for developing effective therapies.
Purpose of the Study:
- To explore the use of tissue engineering platforms for studying angiogenic mechanisms.
- To highlight advanced gene and drug delivery strategies for vascularization.
- To showcase modular tissue engineering as a relevant example.
Main Methods:
- Review of current literature on tissue vascularization and regenerative medicine.
- Analysis of gene and drug delivery systems for promoting angiogenesis.
- Case study of modular tissue engineering applications.
Main Results:
- Tissue engineering platforms offer valuable tools for dissecting angiogenic processes.
- Gene and drug delivery strategies show promise in enhancing vascularization of engineered tissues.
- Modular tissue engineering facilitates controlled vascular network development.
Conclusions:
- Targeting tissue vascularization is a promising therapeutic strategy for ischemic diseases.
- Advanced delivery systems can significantly improve vascularization in tissue engineering.
- Further research into angiogenic mechanisms will drive innovation in regenerative medicine.
